Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Scorpion Sinks Pincers Into Funding Round For PI3K Inhibitor

Jul 16 2024

• By Alaric DeArment

• Source: Shutterstock

Related Content

Status Quo: US Approvals For Pepaxto, Copiktra Remain Intact Despite Negative Panel Reviews

May 05 2023

Kyowa Kirin Tries On New Genes With Orchard Buy

Oct 05 2023

Setback For Alembic-backed Rhizen After Concerns Over PI3K Inhibitors

May 06 2022

Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?

Nov 30 2021

PI3K Inhibitors For Hematology Indications Need Randomized Data, FDA Panel Says

Apr 21 2022

Scorpion Partners Two Assets With Pierre Fabre To Prioritize Investment In A Third

Apr 04 2023

Related Companies

Scorpion Therapeutics, Inc.

Pierre Fabre

Gilead Sciences, Inc.

TG Therapeutics, Inc.

Secura Bio, Inc.

Lite Strategy, Inc.

Kyowa Kirin Co., Ltd.

Novartis AG

Additional Topics

Financing Business Strategies Research & Development Cancer BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window